Exciting new treatment for diffuse-large B-cell lymphoma approved by the European Medicines Agency (EMA).

diffuse-large B-cell lymphoma

In July 2023 the EMA approved Glofitamab, one of the most potent single drugs available for the treatment of relapsed/refractory DLBCL. Glofitamab is a CD20xCD3 bispecific T-cell engager. In a Phase 2 trial of 108 relapsed/refractory DLBCL patients who received glofitamab for a fixed duration an overall response was seen in 50% and a complete … Read more

Diffuse-large B-cell lymphoma – Ground breaking new treatment available for relapsed/refractory patients

Diffuse large B-cell lymphoma

For over 30-years autologous stem cell transplantation has been the standard of care for patients with relapsed diffuse-large B-cell lymphoma (DLBCL). The international Zuma-7 trial randomised 359 patients with relapsed/refractory DLBCL or patients with DLBCL who had relapsed within 12-months of their initial therapy to a novel T-cell immunotherapy called CAR-T (chimeric receptor antigen -T-cell … Read more

Hodgkin Lymphoma? A new standard of care for advanced stage patients

hodgkins lymphoma

For decades the standard treatment for patients with advanced Hodgkin lymphoma has been combination chemotherapy with either ABVD or escalated BEACOPP. Approximately 5 years ago a randomised trial showed that brentuximab vedotin (an antibody conjugate) combined with AVD compared with ABVD improved overall survival in adults with Hodgkin lymphoma. The results of the recent SWOG … Read more